ONCO Stock Overview
Oncopeptides AB (publ), a biotech company, engages in the commercialization, and research and development of treatments for difficult-to-treat hematological diseases in the United States, Europe, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Oncopeptides AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr2.89 |
| 52 Week High | kr11.53 |
| 52 Week Low | kr2.85 |
| Beta | -0.60 |
| 1 Month Change | -45.24% |
| 3 Month Change | -57.41% |
| 1 Year Change | -73.53% |
| 3 Year Change | -97.82% |
| 5 Year Change | -97.81% |
| Change since IPO | -93.28% |
Recent News & Updates
Recent updates
Oncopeptides (STO:ONCO) Will Have To Spend Its Cash Wisely
Feb 29
Oncopeptides (STO:ONCO) Has Debt But No Earnings; Should You Worry?
Nov 14We Think Oncopeptides (STO:ONCO) Needs To Drive Business Growth Carefully
Jul 26Is Oncopeptides (STO:ONCO) In A Good Position To Invest In Growth?
Mar 25Is Oncopeptides (STO:ONCO) In A Good Position To Invest In Growth?
Nov 23Shareholder Returns
| ONCO | SE Biotechs | SE Market | |
|---|---|---|---|
| 7D | -36.3% | 2.5% | -0.7% |
| 1Y | -73.5% | -3.4% | 4.4% |
Price Volatility
| ONCO volatility | |
|---|---|
| ONCO Average Weekly Movement | 20.7% |
| Biotechs Industry Average Movement | 9.5% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in SE Market | 13.1% |
| 10% least volatile stocks in SE Market | 3.5% |
Volatility Over Time: ONCO's weekly volatility has increased from 13% to 21% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 57 | Sofia Heigis | www.oncopeptides.com/sv |
Oncopeptides AB (publ), a biotech company, engages in the commercialization, and research and development of treatments for difficult-to-treat hematological diseases in the United States, Europe, and internationally. Its lead product candidate is melflufen, a drug conjugate for the treatment of relapsed refractory multiple myeloma in adult patients. Oncopeptides AB (publ) was incorporated in 2000 and is headquartered in Stockholm, Sweden
Oncopeptides AB (publ) Fundamentals Summary
| ONCO fundamental statistics | |
|---|---|
| Market cap | kr285.42m |
| Earnings (TTM) | -kr249.11m |
| Revenue (TTM) | kr35.22m |
8.1x
P/S Ratio-1.1x
P/E RatioIs ONCO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ONCO income statement (TTM) | |
|---|---|
| Revenue | kr35.22m |
| Cost of Revenue | -kr1.08m |
| Gross Profit | kr36.30m |
| Other Expenses | kr285.41m |
| Earnings | -kr249.11m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 30, 2024
| Earnings per share (EPS) | -2.52 |
| Gross Margin | 103.06% |
| Net Profit Margin | -707.30% |
| Debt/Equity Ratio | 187.5% |
How did ONCO perform over the long term?
See historical performance and comparison